President Donald Trump threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S. "very soon."  But he suggested that those levies would not go into effect immediately, sayin...

I see a 50-60% chance of a recession in the next 12–24 months, so portfolio preparation is essential. I recommend the iShares Gold Trust Micro as a low-cost gold ETF that has outperformed during re...

In 2013, AbbVie (ABBV -0.93%) became a publicly traded corporation after splitting from its former parent company, Abbott Laboratories (ABT 0.18%). Since then, both have produced strong returns and...

AbbVie (NASDAQ:ABBV) has distinguished itself as one of the top performers in the healthcare sector this year, with its stock rising by 6% while the broader S&P 500 healthcare index fell by 1%. Thi...

ABBV's $2.1 billion Capstan deal and 20+ recent acquisitions sharpen its pipeline edge across immunology and beyond.

Dividend Aristocrats have underperformed the S&P 500 in 2025, with NOBL up 1.77% versus SPY's 5.55% year-to-date gain. Dividend growth remains healthy, with 44 out of 69 Aristocrats already raising...

I don't know if we'll be riding in personal aircraft 20 years from now, like George Jetson did in the cartoon TV series. I don't know if artificial intelligence (AI) will replace millions of jobs.

ABBV adds $24B in market cap as Skyrizi and Rinvoq drive growth post-Humira, with more upside from a strong pipeline.

In the most recent trading session, AbbVie (ABBV) closed at $185.48, indicating a -2.82% shift from the previous trading day.

AbbVie remains a Buy despite venetoclax's MDS trial failure, as this setback has minimal impact on current revenue and growth outlook. SKYRIZI and RINVOQ are successfully replacing HUMIRA's lost re...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

AbbVie's top line is stable post-Humira, with Skyrizi and Rinvoq driving growth, but margin recovery remains uncertain and slow. Pipeline and acquisitions support long-term growth, but macro risks ...

Skyrizi and Rinvoq are rapidly replacing Humira, generating over $5 billion in Q1 2025 alone. From migraine to Parkinson's and obesity, AbbVie is building dominant franchises across multiple high-g...

AbbVie is undervalued, trading at under 16x 2025 earnings, despite robust EPS growth, a strong pipeline, and successful Humira diversification. Skyrizi and Rinvoq are driving immunology revenue, ex...

AbbVie offers a compelling blend of high yield, consistent dividend growth, and strong financials, making it attractive for income-focused investors. The company has successfully transitioned from ...